184 related articles for article (PubMed ID: 24635435)
1. [Interaction between p53 and MDM2 in human lung cancer cells].
Rybárová S; Hodorová I; Vecanová J; Muri J; Mihalik J
Klin Onkol; 2014; 27(1):33-7. PubMed ID: 24635435
[TBL] [Abstract][Full Text] [Related]
2. Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma.
Soslow RA; Shen PU; Chung MH; Isacson C
Int J Gynecol Pathol; 1998 Apr; 17(2):129-34. PubMed ID: 9553809
[TBL] [Abstract][Full Text] [Related]
3. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas.
Shwe M; Chiguchi G; Yamada S; Nakajima T; Maung KK; Takagi M; Amagasa T; Tsuchida N
J Med Dent Sci; 2001 Dec; 48(4):113-9. PubMed ID: 12160248
[TBL] [Abstract][Full Text] [Related]
4. Wild-type p53 overexpression and its correlation with MDM2 and p14ARF alterations: an alternative pathway to non-small-cell lung cancer.
Wang YC; Lin RK; Tan YH; Chen JT; Chen CY; Wang YC
J Clin Oncol; 2005 Jan; 23(1):154-64. PubMed ID: 15625370
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical detection of bcl2, p53, mdm2 and p21/waf1 proteins in small-cell lung carcinomas.
Stefanaki K; Rontogiannis D; Vamvouka C; Bolioti S; Chaniotis V; Sotsiou F; Vlychou M; Delidis G; Kakolyris S; Georgoulias V; Kanavaros P
Anticancer Res; 1998; 18(3A):1689-95. PubMed ID: 9673391
[TBL] [Abstract][Full Text] [Related]
6. Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation.
Koga T; Hashimoto S; Sugio K; Yoshino I; Nakagawa K; Yonemitsu Y; Sugimachi K; Sueishi K
Int J Cancer; 2001 Jul; 95(4):232-9. PubMed ID: 11400116
[TBL] [Abstract][Full Text] [Related]
7. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
[TBL] [Abstract][Full Text] [Related]
8. MDM2 gene amplification and expression in non-small-cell lung cancer: immunohistochemical expression of its protein is a favourable prognostic marker in patients without p53 protein accumulation.
Higashiyama M; Doi O; Kodama K; Yokouchi H; Kasugai T; Ishiguro S; Takami K; Nakayama T; Nishisho I
Br J Cancer; 1997; 75(9):1302-8. PubMed ID: 9155050
[TBL] [Abstract][Full Text] [Related]
9. [TP53 gene aberrations in chondromatous neoplasms: correlation with immunohistochemical p53 accumulation and MDM2 expression].
Blasenbreu S; Baretton GB; Bender C; Haas CJ; Diebold J; Löhrs U
Verh Dtsch Ges Pathol; 1998; 82():284-9. PubMed ID: 10095448
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
[TBL] [Abstract][Full Text] [Related]
11. Abnormal expression of MDM2 in prostate carcinoma.
Leite KR; Franco MF; Srougi M; Nesrallah LJ; Nesrallah A; Bevilacqua RG; Darini E; Carvalho CM; Meirelles MI; Santana I; Camara-Lopes LH
Mod Pathol; 2001 May; 14(5):428-36. PubMed ID: 11353053
[TBL] [Abstract][Full Text] [Related]
12. p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas.
Pacinda SJ; Ledet SC; Gondo MM; Langston C; Brown RW; Carmona PA; Franklin RB; Roggli VL; Cagle PT
Hum Pathol; 1996 Jun; 27(6):542-6. PubMed ID: 8666362
[TBL] [Abstract][Full Text] [Related]
13. [The expression of Mdm2 protein and p53 mutation in lung squamous cell carcinomas and their clinicopathological significance].
Zhang J; Liu H; Li S; Gu C
Zhonghua Jie He He Hu Xi Za Zhi; 1999 Mar; 22(3):163-5. PubMed ID: 11812371
[TBL] [Abstract][Full Text] [Related]
14. A comparative study of P53/MDM2 genes alterations and P53/MDM2 proteins immunoreactivity in soft-tissue sarcomas.
Rieske P; Bartkowiak JK; Szadowska AM; Olborski B; Harezga-Bal B; Debiec-Rychter M
J Exp Clin Cancer Res; 1999 Sep; 18(3):403-16. PubMed ID: 10606188
[TBL] [Abstract][Full Text] [Related]
15. Mdm2 and the p53 pathway in human pituitary adenomas.
Suliman M; Royds J; Cullen D; Timperley W; Powell T; Battersby R; Jones TH
Clin Endocrinol (Oxf); 2001 Mar; 54(3):317-25. PubMed ID: 11298083
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical detection of bcl2, p53, mdm2 and p21/waf1 proteins in small-cell lung carcinomas.
Stefanaki K; Rontogiannis D; Vamvouka C; Bolioti S; Chaniotis V; Sotsiou F; Vlychou M; Delidis G; Kakolyris S; Georgoulias V; Kanavaros P
Anticancer Res; 1998; 18(2A):1167-73. PubMed ID: 9615783
[TBL] [Abstract][Full Text] [Related]
17. Deregulation of p53-MDM2 auto-regulatory pathway in breast carcinoma.
Baliou E; Nonni A; Keramopoulos D; Ragos V; Tsiambas E; Patsouris E; Pavlakis K
J BUON; 2016; 21(5):1099-1103. PubMed ID: 27837610
[TBL] [Abstract][Full Text] [Related]
18. Aberrant expression of pRb, p16, p14ARF, MDM2, p21 and p53 in squamous cell carcinomas of lung.
Xue Q; Sano T; Kashiwabara K; Oyama T; Nakajima T
Jpn J Cancer Res; 2001 Mar; 92(3):285-92. PubMed ID: 11267938
[TBL] [Abstract][Full Text] [Related]
19. p53 and MDM2 expression in oral squamous cell carcinoma.
Matsumura T; Yoshihama Y; Kimura T; Shintani S; Alcalde RE
Oncology; 1996; 53(4):308-12. PubMed ID: 8692535
[TBL] [Abstract][Full Text] [Related]
20. A molecular and immunohistochemical study of the MDM2 protein isoforms and p53 gene product in bronchogenic carcinoma.
Gorgoulis VG; Zoumpourlis V; Rassidakis GZ; Karameris A; Rassidakis AN; Spandidos DA; Kittas C
J Pathol; 1996 Oct; 180(2):129-37. PubMed ID: 8976869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
